Methylphenidate 🚫 denied access to WHO’s list of essential medicines 💊 for the third time ⏳
Read Full Article
#MethylphenidateDenied #WHOEssentialMedicines #AccessToMedicine #GlobalHealthPolicy #HealthEquity
Read Full Article
#MethylphenidateDenied #WHOEssentialMedicines #AccessToMedicine #GlobalHealthPolicy #HealthEquity
BMJ Evidence-Based Medicine
Methylphenidate denied access to WHO’s list of essential medicines for the third time
Attention-deficit/hyperactivity disorder (ADHD) affects 3%–5% of children and about 2.5% of adults, though prevalence varies across regions.1 The psychostimulant methylphenidate is widely used as first-line treatment in many health systems.2
The WHO updates…
The WHO updates…
❤2